Domainex, a Cambridge, UK-based biotechnology company, has secured an undisclosed sum from Longbow, The Capital Fund, Bury Fitzwilliam-Lay & Partners LLP, and Takeda Research Investment, Inc. (TRI).
The capital infusion will enable the company to develop its Combinatorial Domain Hunting (CDH) technology, and to advance its internal pipeline of oncology targets.
In particular, the company will take forward its small-molecule drug research portfolio consisting of the kinase IKKe, and a number of methyltransferase enzymes.
According to a press release, this funding should bring Domainex to a point where it can close a number of corporate collaborations and deals on its novel targets for cancer.
Founded in 2002, Domainex operates laboratories in the Cambridge Science Park and offices in the London Bioscience Innovation Centre.